STOCKHOLM, April 24, 2019 /PRNewswire/ -- (The previous
release was sent at 10.23 CET and has been updated with accurate
dates in the key indicators of the Swedish version. The correct
dates refer to the years 2018 and 2019. Nothing else differs from
the previous release.)
During the first quarter of 2019, we remained focused on our
product launch strategy and continued to create value, as we
reached several key objectives and took several steps towards the
commercialization of IMMray™ PanCan-d, our diagnostic test for
early detection of pancreatic cancer.
Another key objective that we reached in the first quarter was
the addition of new participants to our PanFAM-1 study, a
multicenter prospective validation study for early diagnosis of
people with a high risk of hereditary pancreatic cancer. In Q1 2019
we added two additional centers, one in Sweden and one in Spain. Umeå University Hospital in
Sweden and Catalan Institute of
Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute
(IDIBELL) in Barcelona are now
part of PanFAM-1 study.
We also took an extremely important step towards on the
optimization of the algorithm during Q1. We announced in March that
using blood samples that are as fresh as possible, i.e. stored for
less than 24 months, increases the test performance and provides
optimal results. We were able to attain the relevant samples
through our large and growing network of clinical Key Opinion
Leaders (KOL). It is imperative to note that we needed samples that
best mirror the blood samples that will be used with our final
product, finding these fresh samples and gaining access to them is
quite difficult and takes time.
With the appointment of Julie
Silber as Senior Investor Relations Director early this year
we actualized a strategic objective in strengthening the IR role
and our shareholder communication capabilities at Immunovia.
We continued to work intensely during the first quarter of 2019
on the preparations for our sales launch targeted for the beginning
of 2020.
Excerpt from the CEO Mats
Grahn's comment on the report.
Key Indicators
Key Indicators (SEK
thousand unless otherwise stated)
|
Jan-Mar
2019
|
Jan-Mar
2018
|
Full year
2018
|
Full year
2017
|
Net Sales
|
66
|
112
|
333
|
149
|
Operating
earnings
|
-27,197
|
-17,377
|
-87,708
|
-45,520
|
Earnings before
tax
|
-26,381
|
-17,326
|
-86,531
|
-45,323
|
Net
earnings
|
-26,384
|
-17,326
|
-86,536
|
-45,232
|
Earnings per share
before and after dilution (SEK/share)
|
-1.35
|
-1.00
|
-4.67
|
-2.67
|
Equity ratio,
%
|
89
|
94
|
97
|
94
|
No. of shares at the
end of the period
|
19,531,353
|
17,318,059
|
19,531,353
|
17,318,059
|
This financial statement has been produced in accordance with
IFRS for the Immunovia Group, which comprises Immunovia AB and the
wholly-owned subsidiaries Immunovia Incentive AB, Immunovia Inc.
and Immunovia GmbH.
Outlook
Immunovia is focused on fundamentally
transforming diagnosis of complex forms of cancer and autoimmune
diseases. The antibody-based platform, IMMray™, is the result of 15
years of research at CREATE Health – the Center for Translational
Cancer Research at Lund
University, Sweden. IMMray™ is a
technology platform for the development of diagnostic tests and the
company's primary test, IMMray™ PanCan–d, is the first test in the
world for early diagnosis of pancreatic cancer.
The Company reiterates it's financial targets in accordance with
what has previously been disclosed. The company anticipates the
first revenues from self pay sales in early 2020.The following
financial targets have been established:
- Immunovia's target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for
IMMray™ PanCan–d.
- Immunovia's target is to achieve total turnover, including
payment via self-pay and cost remuneration from insurance systems,
of SEK 800-1,000 million by
2024.
Immunovia invites to a teleconference (in English) for
investors, analysts and media on Monday
April 29, at 3:00 – 4:00 p.m.
CET.
Mats Grahn, CEO will present
Immunovia and comment on the interim report for the period
January-March 2019, give an update
from the Annual General Meeting on April
26, followed by a Q&A session. Please call in a few
minutes in advance.
To attend, please dial-in at one of the numbers below:
BE: +3226200547
DK: +4578150110
FR: +33170750775
DE: +496913803452
NO: +4723500236
SE: +46856642695
CH: +41225675632
NL: +31207219495
UK: +443333009274
US: +18335268383
For questions or interview
bookings:
ir@immunovia.com
There will be an MP3-file available at Immunovia's webpage under
Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
For more information, please
contact:
Julie
Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel:
+46-7-93-486-277
About Immunovia
Immunovia AB was founded in
2007 by investigators from the Department of Immunotechnology at
Lund University and CREATE Health,
the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases diagnosis,
prognosis and therapy monitoring. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/correction--immunovia-interim-report--january-march-2019,c2795753
The following files are available for download:
https://mb.cision.com/Main/13121/2795753/1031047.pdf
|
Immunovia Interim
Report, January-March 2019
|
View original
content:http://www.prnewswire.com/news-releases/correction-immunovia-interim-report-january-march-2019-300837449.html
SOURCE Immunovia AB